Skip to main content
SpringerLink
Log in

Corticosteroids, Dopamine Antagonists, and Other Drugs

  • Conference paper
Perugia Consensus Conference on Antiemetic Therapy

  • 44 Accesses

Abstract

The literature on corticosteroids, dopamine antagonists, and other antiemetics, such as cannabinoids and benzodiazepines, was reviewed and presented at a consensus conference on antiemetics. Based on the reviews and the discussion during the conference, guidelines for the use of these agents are given.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 84.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 109.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Similar content being viewed by others

References

  1. Aapro MS (1991) Present role of corticosteroids as antiemetics. Recent Results Cancer Res 121: 91–100

    PubMed  CAS  Google Scholar 

  2. Aapro MS (1996) Therapeutic approach to delayed emesis. In: Tonato M (ed) Anti-emetics in the supportive care of cancer patients. Springer, Berlin Heidelberg New York, pp 73–77

    Google Scholar 

  3. Aapro MS, Alberts DS (1981) High-dose dexamethasone for prevention of cisplatininduced vomiting. Cancer Chemother Pharmacol 7: 11–14

    Article  PubMed  CAS  Google Scholar 

  4. Aapro MS, Alberts DS, Serokman R (1983) Lack of dexamethasone effect on the antitumor activity of cisplatin. Cancer Treat Rep 67: 1013–1017

    PubMed  CAS  Google Scholar 

  5. Ahmedzai S, Carlyle DL, Calder IT, Moran F (1983) Antiemetic efficacy and toxicity of nabilone, a synthetic cannabinoid in lung cancer chemotherapy. Br J Cancer 48: 657–663

    Article  PubMed  CAS  Google Scholar 

  6. Al-Ghamdi MS, Ibrahim EM, Al-Idrissi HY, Al-Khatti AA, Al-Faraj A (1991) Antiemetic efficacy of cimetidine randomized, double-blind, crossover study with dexamethasone in cancer patients receiving emetogenic chemotherapy. Ann Oncol 2: 517–518

    PubMed  CAS  Google Scholar 

  7. Arnold DJ, Ribiero V, Bullcin W (1980) Metoclopramide versus prochlorperazine in the prevention of vomiting from diamminedichloroplatinum (abstract). Proc Clin Oncol 21: 344

    Google Scholar 

  8. Basurto C, Roila F, Bracardi S, Tonato M, Ballatori E, Del Favero A (1988) A double-blind trial comparing antiemetic efficacy and toxicity of metoclopramide versus methylprednisolone versus domperidone in patients receiving doxorubicin chemotherapy alone or in combination with other antiblastic agents. Am J Clin Oncol 11: 594–596

    Article  PubMed  CAS  Google Scholar 

  9. Belt RI, Rhodes J, Taylor S (1981) Antiemetic therapy for patients receiving cisdiamminedichloroplatinum(II): a randomized, double-blind study comparing metoclopramide and prochlorperazine. In: Poster DS, Penta JS, Bruno S, (eds) Treatment of cancer chemotherapy-induced nausea and vomiting. Masson, New York, pp 153–158

    Google Scholar 

  10. Bennett JM, Byrne P, Desai A et al (1985) A randomized multicenter trial for cyclophosphamide, Novantrone and 5-fluorouracil (CNF) versus cyclophosphamide, Adriamycin and 5-fluorouracil ( CAF) in patients with metastatic breast cancer. Invest New Drugs 3: 179–185

    Article  PubMed  CAS  Google Scholar 

  11. Bleiberg H, Piccart M, Lips S, Panzer JM, N’Koua Mbon JB (1992) A phase I trial of a new antiemetic drug–clebopride malate–in cisplatin-treated patients. Ann Oncol 3: 141–143

    PubMed  CAS  Google Scholar 

  12. Bloom BS (1989) Risk and cost of gastrointestinal side effects associated with non-steroidal anti-inflammatory drugs. Arch Intern Med 149: 1019–1022

    Article  PubMed  CAS  Google Scholar 

  13. Bonneterre J, Chevallier B, Metz R et al (1990) A randomized double-blind comparison of ondansetron and metoclopramide in the prophylaxis of emesis induced by cyclophosphamide, fluorouracil, and doxorubicin or epirubicin chemotherapy. J Clin Oncol 8: 1063–1069

    PubMed  CAS  Google Scholar 

  14. Bregni M, Siena S, Di Nicola M, Bonadonna G, Gianni AM (1991) Tropisetron plus haloperidol to ameliorate nausea and vomiting associated with high-dose alkylating agent cancer chemotherapy. Eur J Cancer 27: 561–565

    Article  PubMed  CAS  Google Scholar 

  15. Campbell M, Bateman DN (1992) Pharmacokinetic optimisation of antiemetic therapy. Clin Pharmacokinet 23: 147–160

    Article  PubMed  CAS  Google Scholar 

  16. Carr BI, Blayney DW, Goldberg A, Braly P, Metter GE, Doroshow JH (1987) High doses of prochlorperazine for cisplatin-induced emesis. A prospective, random, dose-response study. Cancer 60: 2165–2169

    Google Scholar 

  17. Cassileth PA, Lusk EJ, Torri S, DiNubile N, Gerson SL (1983) Antiemetic efficacy of dexamethasone therapy in patients receiving cancer chemotherapy. Arch Int Med 43: 1347–1349

    Article  Google Scholar 

  18. Cersosimo RJ, Bromer R, Hoffer S, Welch J, Abrahamson M, Ki Hong W (1985) The antiemetic activity of droperidol administered by intramuscular injection during cisplatin chemotherapy: a pilot study. Drug Intell Clin Pharmacol 19: 118–121

    CAS  Google Scholar 

  19. Chevallier B, Cappelaere P, Splinter T et al (1997) A double-blind, multicentre comparison of intravenous dolasetron mesilate and metoclopramide in the prevention of nausea and vomiting in cancer patients receiving high-dose cisplatin chemotherapy. Support Care Cancer 5: 22–30

    Article  PubMed  CAS  Google Scholar 

  20. Chiara S, Campora E, Lionetto R, Bruzzi P, Rosso R (1987) Methylprednisolone for the control of CMF-induced emesis. Am J Clin Oncol 10: 264–267

    Article  PubMed  CAS  Google Scholar 

  21. Clavel M, Bolot JE, Philippe-Bert J, Putot JP, Rodary C, Pommatau E (1978) Essai comparatif en double insu de deux doses i.v. (50 mg et 10 mg) de metopimazine (1) dans la prevention de nausées et des vomissements de la chimiotherapie anticancéreuse. Lyon Med 239: 307–309

    Google Scholar 

  22. Coils BM, Ferry PG, Gray AJ, Harvey VJ, McQueen EG (1980) The antiemetic activity of tetrahydrocannabinol versus metoclopramide and thiethylperazine in patients undergoing cancer chemotherapy. N Z Med J 91: 449–451

    Google Scholar 

  23. Cox R, Newman CE, Leyland MJ (1982) Metoclopramide in the reduction of nausea and vomiting associated with combined chemotherapy. Cancer Chemother Pharmacol 8: 133–135

    Article  PubMed  CAS  Google Scholar 

  24. Cunningham D, Soukop M, Gilchrist NL et al (1985) Randomised trial of intravenous high dose metoclopramide and intramuscular chlorpromazine in controlling nausea and vomiting induced by cytotoxic drugs. BMJ 290: 604–605

    Article  PubMed  CAS  Google Scholar 

  25. Cunningham D, Evans C, Gazet J-C et al (1987) Comparison of antiemetic efficacy of domperidone, metoclopramide, and dexamethasone in patients receiving outpatient chemotherapy regimens. BMJ 295: 256

    Article  Google Scholar 

  26. Cunningham D, Bradley CJ, Forrest GJ et al (1988) A randomized trial of oral nabilone and prochlorperazine compared to intravenous metoclopramide and dexamethasone in the treatment of nausea and vomiting induced by chemotherapy regimens containing cisplatin or cisplatin analogues. Eur J Cancer Clin Oncol 24: 686–689

    Article  Google Scholar 

  27. Cunningham D, Turner A, Hawthorn J (1989) Ondansetron with and without dexamethasone to treat chemotherapy-induced emesis. Lancet I: 13–23

    Google Scholar 

  28. Lebeau B, Depierre A, Giovanni M et al (1996) The efficacy of a combination of ondansetron, methylprednisolone and metopimazine in patients previously uncontrolled with a dual antiemetic treatment in cisplatin-based chemotherapy. Ann Oncol 8: 887–892

    Article  Google Scholar 

  29. De Wit R, Schmitz PIM, Verweij J et al (1996) Analysis of cumulative probabilities shows that the efficacy of 5-HT3 antagonist prophylaxis is not maintained. J Clin On-col 14: 644–651

    Google Scholar 

  30. Drapkin RL, Sold GH, Paladine WJ, Polackwich R, Lyman G et al (1982) The antiemetic effect and dose response of dexamethasone in patients receiving cis-platinum (abstract). Proc Am Soc Clin Oncol 1: 64

    Google Scholar 

  31. D’Souza DP, Reyntjens A, Thomas RD (1980) Domperidone in the prevention of nausea and vomiting induced by antineoplastic agents: a three-fold evaluation. Curr Ther Res 27: 384–390

    Google Scholar 

  32. DuBois A, Vach W, Wechsel U, (1996) 5-Hydroxyindole-acetic acid and cortisol excretion as predictors of chemotherapy-induced emesis. Br J Cancer 74: 1137–1140

    Google Scholar 

  33. Ekert H, Waters KD, Jurk IH, Mobilia J, Loughnan P (1979) Ameloration of cancer chemotherapy-induced nausea and vomiting by delta-9-tetrahydrocannabinol. Med J Aust 2: 657–659

    PubMed  CAS  Google Scholar 

  34. Fauser AA, Bleiberg H, Chevallier B et al (1996) A double-blind, randomized, parallel study of IV dolasetron mesilate versus IV metoclopramide in patients receiving moderately emetogenic chemotherapy. Cancer J 9: 196–202

    Google Scholar 

  35. Fredrikson M, Hursti T, Fârst CJ et al (1992) Nausea in cancer chemotherapy is inversely related to urinary cortisol excretion. Br J Cancer 65: 779–780

    Article  PubMed  CAS  Google Scholar 

  36. Frytak S, Moertel CG, O’Fallon JR et al (1979) Delta-9-tetrahydrocannabinol as an antiemetic for patients receiving cancer chemotherapy. Ann Intern Med 91: 825–830

    PubMed  CAS  Google Scholar 

  37. Frytak S, Moertel CG, Eagan RT, O’Fallon JR (1981) A double-blind comparison of metoclopramide and prochlorperazine as antiemetics for platinum therapy (abstract). Proc Am Soc Clin Oncol 22: 421

    Google Scholar 

  38. Gercovich FG, Nahmod VE, Pirola CJ, Morgenfeld EL, Rivarola EJ (1984) A double-blind randomized, cross-over study comparing domperidone to metoclopramide as antiemetic prevention in cancer chemotherapy (abstract). Proc Am Soc Clin Oncol 3: 89

    Google Scholar 

  39. Goldstein D, Levi JA, Woods RL, Russel J, Morgan J, Kerestes Z (1989) Double-blind randomized cross-over trial of dexamethasone and prochlorperazine as anti-emetics for cancer chemotherapy. Oncology 46: 105–108

    Article  PubMed  CAS  Google Scholar 

  40. Gordon CJ, Pazdur R, Zicarelli A, Cummings G, Al-Sarraf M (1989) Metoclopramide versus metoclopramide and lorazepam: superiority of combined therapy in the control of cisplatin-induced emesis. Cancer 63: 578–582

    Article  PubMed  CAS  Google Scholar 

  41. Gralla RJ, Itri L, Pisko S, et al (1981) Antiemetic efficacy of high-dose metoclopramide: randomized trials with placebo and prochlorperazine in patients with chemotherapy-induced vomiting. N Engl J Med 305: 905–909

    Article  PubMed  CAS  Google Scholar 

  42. Greenberg DB, Surman OS, Clarke J, Baer L (1987) Alprazolam for phobic nausea and vomiting related to cancer chemotherapy. Cancer Treat Rep 71: 549–560

    PubMed  CAS  Google Scholar 

  43. Grossman B, Lessin LS, Cohen P (1979) Droperidol prevents nausea and vomiting from cis-platinum. N Engl J Med 301: 47

    PubMed  CAS  Google Scholar 

  44. Grunberg SM (1993) Potential for combination therapy with the new antiserotonergic agents. Eur J Cancer [A] 29 [Suppl 1]: S39 - S41

    Article  Google Scholar 

  45. Grunberg SM, Gala KV, Lampenfeld M et al (1984) Comparison of the antiemetic effect of high-dose intravenous metoclopramide and high-dose intravenous haloperidol in a randomized double-blind crossover study. J Clin Oncol 2: 782–787

    PubMed  CAS  Google Scholar 

  46. Grunberg SM, Akerley WL, Krailo MD, Johnson KB, Baker CR, Cariffe PA (1986) Comparison of metoclopramide and metoclopramide plus dexamethasone for complete protection from cisplatin-induced emesis. Cancer Invest 4: 379–385

    Article  PubMed  CAS  Google Scholar 

  47. Grunewald HW, Rosner F (1984) Dexamethasone as an antiemetic during cancer chemotherapy. Ann Intern Med 101: 398

    Google Scholar 

  48. Haid M (1984) Steroid antiemesis may be harmful. N Engl J Med 304: 1237

    Google Scholar 

  49. Hamik A, Peroutka SJ (1989) Differential interactions of traditional and novel anti-emetics with dopamine D2 and 5-hydroxytryptamine3 receptors. Cancer Chemother Pharmacol 2: 307–310

    Article  Google Scholar 

  50. Harris AL (1982) Cytotoxic-therapy-induced vomiting is mediated via enkephalin pathways. Lancet I: 714

    Google Scholar 

  51. Herman TS, Einhorn LH, Jones SE et al (1979) Superiority of nabilone over prochlorperazine as an antiemetic in patients receiving cancer chemotherapy. N Engl J Med 300: 1295–1297

    Article  PubMed  CAS  Google Scholar 

  52. Herrstedt J, Hannibal J, Hallas J, Andersen E, Lauersen LC, Hansen M (1991) High-dose metoclopramide+lorazepam versus low-dose metoclopramide+lorazepam+dehydrobenzperidol in the treatment of cisplatin-induced nausea and vomiting. Ann Oncol 2: 223–227

    PubMed  CAS  Google Scholar 

  53. Herrstedt J, Hyttel J, Pedersen J (1993) Interaction of the antiemetic metopimazine and anticancer agents with brain dopamine D2, 5-hydroxytryptamine3, histamine H1, muscarine cholinergic and a-1 adrenergic receptors. Cancer Chemother Pharmacol 33: 53–56

    Article  PubMed  CAS  Google Scholar 

  54. Herrstedt J, Sigsgaard T, Boesgaard M, Jensen TP, Dombernowsky P (1993) Ondansetron plus metopimazine compared with ondansetron alone in patients receiving moderately emetogenic chemotherapy. N Engl J Med 328: 1076–1080

    Article  PubMed  CAS  Google Scholar 

  55. Herrstedt J, Sigsgaard T, Angelo HR, Kampmann JP, Hansen M (1997) Dose-finding study of oral metopimazine. Support Care Cancer 5: 38–43

    Article  PubMed  CAS  Google Scholar 

  56. Herrstedt J, Sigsgaard T, Handberg J, Schousboe BMB, Hansen M, Dombernowsky P (1997) Randomized, double-blind comparison of ondansetron versus ondansetron plus metopimazine as antiemetic prophylaxis during platinum-based chemotherapy. J Clin Oncol 15: 1690–1696

    PubMed  CAS  Google Scholar 

  57. Hesketh PJ, Gandara DR, Hainsworth J, Edelman M, Webber LM, McManus M (1996) Addition of the dopamine D2 antagonist prochlorperazine to granisetron/dexamethasone: improved control of acute emesis from high dose cisplatin (abstract). Proc Am Soc Clin Oncol 15: 540

    Google Scholar 

  58. Homesley HD, Gainey JM, Jobson VN et al (1982) Double-blind placebo-controlled study of metoclopramide in cisplatin-induced emesis. N Engl J Med 307: 250–251

    Google Scholar 

  59. Hursti TJ, Fredrikson M, Steineck G et al (1993) Endogenous cortisol exerts anti-emetic effect similar to that of exogenous corticosteroids. Br J Cancer 68: 112–114

    Article  PubMed  CAS  Google Scholar 

  60. Israel L, Rodary C (1978) Treatment of nausea and vomiting related to anticancerous multiple combination chemotherapy: results of two controlled studies. J Int Med Res 6: 235–240

    PubMed  CAS  Google Scholar 

  61. Italian Group for Antiemetic Research (1995) Dexamethasone, granisetron, or both for the prevention of nausea and vomiting during chemotherapy for cancer. N Engl J Med 332: 1–5

    Article  Google Scholar 

  62. Jones AL, Hill AS, Soukop M et al (1991) Comparison of dexamethasone and ondansetron in the prophylaxis of emesis induced by moderately emetogenic chemotherapy. Lancet 338: 483–487

    Article  PubMed  CAS  Google Scholar 

  63. Joss RA, Galeazzi RL, Bischoff AK, Pirovino M, Ryssel HJ, Brunner KW (1986) The antiemetic activity of high-dose alizapride and high-dose metoclopramide in patients receiving cancer chemotherapy: a prospective randomized, double-blind trial. Clin Pharmacol Ther 39: 619–624

    Article  PubMed  CAS  Google Scholar 

  64. Kaasa S, Kvaloy S, Dicato M et al (1990) A comparison of ondansetron with metoclopramide in the prophylaxis of chemotherapy-induced nausea and vomiting: a randomized, double-blind study. Eur J Cancer 26: 311–314

    Article  PubMed  CAS  Google Scholar 

  65. Kahn T, Elias EG, Mason GR (1978) A single dose of metoclopramide in the control of vomiting from cis-dichlorodiammineplatinum(II) in man. Cancer Treat Rep 62: 1106–1107

    PubMed  CAS  Google Scholar 

  66. Kelley SL, Braun TJ, Meyer TJ, Rempel P, Pearlman NW (1986) Trial of droperidol as an antiemetic in cisplatin chemotherapy. Cancer Treat Rep 70: 469–472

    PubMed  CAS  Google Scholar 

  67. Kessler JF, Alberts DS, Aapro MS et al (1986) An effective five-drug antiemetic combination for prevention of chemotherapy-related nausea and vomiting. Experience in eighty-four patients. Cancer Chemother Pharmacol 12: 282–286

    Article  Google Scholar 

  68. Koval E, Garay G (1983) Metoclopramide or domperidone in the prevention of chemotherapy-induced nausea and vomiting (abstract). Second European Conference on Clinical Oncology, November 1983, Amsterdam, A23–03

    Google Scholar 

  69. Kris MG, Gralla RJ, Tyson LB, et al (1985) Improved control of cisplatin-induced emesis with high-dose metoclopramide and with combinations of metoclopramide, dexamethasone, and diphenhydramine. Cancer 55: 527–534

    Article  PubMed  CAS  Google Scholar 

  70. Kris MG, Gralla RJ, Clark RA, Tyson LB, Groshen S (1987) Antiemetic control and prevention of side effects of anticancer therapy with lorazepam or diphenhydramine when used in combination with metoclopramide plus dexamethasone. Cancer 60: 2816–2822

    Article  PubMed  CAS  Google Scholar 

  71. Kris MG, Gralla RJ, Tyson LB, Clark RA, Cirrincione C, Groshen S (1989) Controlling delayed vomiting: double-blind, randomized trial comparing placebo, dexamethasone alone, and metoclopramide plus dexamethasone in patients receiving cisplatin. J Clin Oncol 7: 108–114

    PubMed  CAS  Google Scholar 

  72. Lane M, Vogel CL, Ferguson J et al (1991) Dronabinol and prochlorperazine in combination for treatment of cancer chemotherapy-induced nausea and vomiting. J Pain Symptom Manage 6: 352–359

    Article  PubMed  CAS  Google Scholar 

  73. Lee C-W, Suh C-W, Lee J-S et al (1994) Ondansetron compared with ondansetron plus metoclopramide in the prevention of cisplatin-induced emesis. J Korean Med Sci 9: 369–375

    PubMed  CAS  Google Scholar 

  74. Levitt M, Sharma RN, Faiman C et al (1979) Normal metyrapone response after 1 month of high-dose methylprednisolone in cancer patients: a phase I study. Cancer Treat Rep 63: 1327–1330

    PubMed  CAS  Google Scholar 

  75. Livera P, Trojano M, Simone IL et al (1985) Acute changes in blood CSF barrier perm-selectivity to serum proteins after intrathecal methotrexate and CNS irradiation. J Neurol 231: 336–339

    Article  Google Scholar 

  76. Longo DL, Wesley M, Howser D, Hubbard SM, Anderson T, Young RC (1982) Results of a randomized, double-blind crossover trial of scopolamine versus placebo administered by transdermal patch for the control of cisplatin-induced emesis. Cancer Treat Rep 66: 1975–1976

    PubMed  CAS  Google Scholar 

  77. Marini G, Murray S, Goldhirsch A et al (1996) The effect of adjuvant prednisone combined with CMF on patterns of relapse and occurrence of second malignancies in patients with breast cancer. Ann Oncol 7: 245–250

    PubMed  CAS  Google Scholar 

  78. Markman M, Sheidler V, Ettinger DS, Quaskey SA, Mellits EA (1984) Antiemetic efficacy of dexamethasone. Randomized, double-blind, crossover study with prochlorperazine in patients receiving cancer chemotherapy. N Engl J Med 311: 549–552

    Google Scholar 

  79. Marschner NW, Adler M, Nagel GA, Christmann D, Fenzl E, Upadhyaya B (1991) Double-blind randomised trial of the antiemetic efficacy and safety of ondansetron and metoclopramide in advanced breast cancer patients treated with epirubicin and cyclophosphamide. Eur J Cancer 27: 1137–1140

    Article  PubMed  CAS  Google Scholar 

  80. Marty M, Pouillart P, Scholl S et al (1990) Comparison of the 5-hydroxytryptamine3 antagonist ondansetron (GR 38032F) with high dose metoclopramide in the control of cisplatin-induced emesis. N Engl J Med 322: 816–821

    Article  PubMed  CAS  Google Scholar 

  81. Matsumoto I, Aikawa T, Kanda T et al (1989) Amelioration of cisplatin-induced vomiting and anorexia by methylprednisolone. Gan To Kagaku Ryoko 16: 833–838

    CAS  Google Scholar 

  82. Meden H, Meissner O, Conrad A, Kuhn W (1996) Improved control of nausea and emesis with a new bromazepam-containing ondansetron regimen in ovarian cancer patients receiving chemotherapy with carboplatin and cyclophosphamide. Eur J Gynaecol Oncol 17: 114–122

    PubMed  CAS  Google Scholar 

  83. Mellink WA, Blijham GH, Van Deyk WA (1984) Amitriptyline plus fluphenazine to prevent chemotherapy-induced emesis in cancer patients: a double-blind randomized cross-over study. Eur J Cancer Clin Oncol 20: 1147–1150

    Article  PubMed  CAS  Google Scholar 

  84. Meyer BR, O’Mara V, Reidenberg MM (1987) A controlled clinical trial of the addition of transdermal scopolamine to a standard metoclopramide and dexamethasone antiemetic regimen. J Clin Oncol 5: 1994–1997

    PubMed  CAS  Google Scholar 

  85. Miner WD, Sanger GJ (1986) Inhibition of cisplatin-induced vomiting by selective 5-hydroxytryptamine M-receptor antagonism. Br J Pharmacol 88: 497–499

    PubMed  CAS  Google Scholar 

  86. Moertel CG, Reitemeier RJ (1969) Controlled clinical studies of orally administered antiemetic drugs. Gastroenterology 56: 262–268

    Google Scholar 

  87. Moertel CG, Reitemeier RJ (1973) Controlled studies of metopimazine for the treatment of nausea and vomiting. J Clin Pharmacol 13: 283–287

    PubMed  CAS  Google Scholar 

  88. Moertel CG, Reitemeier RJ, Gage RP (1963) A controlled clinical evaluation of anti-emetic drugs. JAMA 186: 116–118

    PubMed  CAS  Google Scholar 

  89. Moreno I, Rosell R, Abad A et al (1992) Comparison of three protracted antiemetic regimens for the control of delayed emesis in cisplatin-treated patients. Eur J Cancer [A] 28: 1344–1347

    Article  Google Scholar 

  90. Morran C, Smith DC, Anderson DA, McArdle CS (1979) Incidence of nausea and vomiting with cytotoxic chemotherapy: a prospective randomised trial of antiemetics. BMJ 19: 1323–1324

    Article  Google Scholar 

  91. Neidhart JA, Gagen M, Young D, Wilson HE (1981) Specific antiemetics for specific cancer chemotherapeutic agents: haloperidol versus benzquinamide. Cancer 47: 1439–1443

    Article  PubMed  CAS  Google Scholar 

  92. Olver IN, Webster LK, Bishop JF, Clarke J, Hillcoat BL (1989) A dose finding study of prochlorperazine as an antiemetic for cancer chemotherapy. Eur J Cancer Clin Oncol 25: 1457–1461

    Article  PubMed  CAS  Google Scholar 

  93. Olver IN, Wolf M, Laidlaw C et al (1992) A randomised double-blind study of high-dose intravenous prochlorperazine versus high-dose metoclopramide as antiemetics for cancer chemotherapy. Eur J Cancer [A] 28: 1798–1802

    Article  Google Scholar 

  94. Onsrud M, Moxnes A, Sollien A et al (1988) High-dose versus low-dose metoclopramide in the prevention of cisplatin-induced emesis. Cancer 61: 2429–2432

    Article  PubMed  CAS  Google Scholar 

  95. Orr LE, McKerman JF, Bloome B (1980) Antiemetic effect of tetrahydrocannabinol compared with placebo and prochlorperazine in chemotherapy-associated nausea and vomiting. Arch Intern Med 140: 1431–1433

    Article  PubMed  CAS  Google Scholar 

  96. Plasse TF, Gorter RW, Krasnow SH, Lane M, Shepard KV, Wadleigh RG (1991) Recent clinical experience with dronabinol. Pharmacol Biochem Behav 40: 695–700

    Article  PubMed  CAS  Google Scholar 

  97. Poilera CF, Nardi M, Marolla P, Pinnaro P, Terzoli E, Giannarelli D (1989) Effective control of CMF-related emesis with high-dose dexamethasone: results of a double-blind crossover trial with metoclopramide and placebo. Am J Clin Oncol 12: 524–529

    Article  Google Scholar 

  98. Pollera CF, Nardi M, Marolla P, Calabresi F (1991) Alizapride alone or alizapride-dexamethasone compared with metoclopramide-dexamethasone in patients at high risk of acute emesis after cisplatin. Acta Oncol 30: 725–729

    PubMed  CAS  Google Scholar 

  99. Powell CB, Mutch DG, Ming-Shian K et al (1990) Dexamethasone used as an antiemetic in chemotherapy protocols inhibits natural cytotoxic cell activity. Cancer 65: 466–472

    Article  PubMed  CAS  Google Scholar 

  100. Roila F, Tonato M, Basurto C et al (1987) Antiemetic activity of high doses of metoclopramide combined with methylprednisolone versus metoclopramide alone in cisplatin-treated cancer patients: a randomized double-blind trial of the Italian Oncology Group for Clinical Research. J Clin Oncol 5: 141–149

    PubMed  CAS  Google Scholar 

  101. Roila F, Tonato M, Basurto C, Minotti V, Ballatori E, Del Favero A (1987) Double-blind controlled trial of the antiemetic efficacy and toxicity of methylprednisolone (MP), metoclopramide (MTC) and domperidone (DMP) in breast cancer patients treated with i.v. CMF. Eur J Cancer Clin Oncol 23: 615–617

    Google Scholar 

  102. Roila F, Basurto C, Minotti V et al (1988) Methylprednisolone versus metoclopramide for prevention of nausea and vomiting in breast cancer patients treated with cyclophosphamide, methotrexate and 5-fluorouracil: a double-blind randomized study. Oncology 45: 346–349

    Article  PubMed  CAS  Google Scholar 

  103. Roila F, Tonato M, Ballatori E, Del Favero A (1996) Comparative studies of various antiemetic regimens. Support Care Cancer 4: 270–280

    Article  PubMed  CAS  Google Scholar 

  104. Rudd JA, Bunce KT, Naylor RJ (1996) The interaction of dexamethasone with ondansetron on drug-induced emesis in the ferret. Neuropharmacology 35: 91–97

    Article  PubMed  CAS  Google Scholar 

  105. Sallan SE, Cronin C, Zelen M, Zinberg NE (1980) Antiemetics in patients receiving chemotherapy for cancer. A randomized comparison of delta-9-tetrahydrocannabinol and prochlorperazine. N Engl J Med 302: 135–138

    Article  PubMed  CAS  Google Scholar 

  106. Saller R, Hellenbrecht D, Hellstern A, Hess H (1985) Improved benefit/risk ratio of higher-dose metoclopramide therapy during cisplatin-induced emesis. Eur J Clin Pharmacol 29: 311–312

    Article  PubMed  CAS  Google Scholar 

  107. Sherlock P, Hartmann WH (1962) Adrenal steroids and the pattern of metastases of breast cancer. JAMA 181: 313–317

    PubMed  CAS  Google Scholar 

  108. Stephen LC, Rine J et al (1981) The role of prostaglandins in the excessive nausea and vomiting after intravascular cis-platinum therapy. Gynecol Oncol 12: 89–91

    Article  Google Scholar 

  109. Swann IL, Thompson EN, Qureshi K (1979) Domperidone or metoclopramide in preventing chemotherapeutically induced nausea and vomiting. BMJ II: 1188–1189

    Google Scholar 

  110. Tsukuda M, Furukawa S, Kokatsu T, Enomoto H, Kubota A, Furukawa M (1995) Comparison of granisetron alone and granisetron plus hydroxyzine hydrochloride for prophylactic treatment of emesis induced by cisplatin chemotherapy. Eur J Cancer [A] 31: 1647–1649

    Article  Google Scholar 

  111. Vallejo C, Rabinovich M, Leone B, Gonzales J (1988) Toxicity and dose response of intravenous (I.V.) metopimazine (MTZ) as preventive of high-dose cisplatin ( CDDP)induced emesis (abstract ). Proc Am Soc Clin Oncol 7: 286

    Google Scholar 

  112. Warr D (1997) Standard treatment of chemotherapy-induced emesis. Support Care Cancer 5: 12–16

    Article  PubMed  CAS  Google Scholar 

  113. Warr D, Willan A, Fine S et al (1991) Superiority of granisetron to dexamethasone plus prochlorperazine in the prevention of chemotherapy-induced emesis. J Natl Cancer Inst 83: 1169–1173

    Article  PubMed  CAS  Google Scholar 

  114. Williams CJ, Bolton A, De Pemberton R, Whitehouse JMA (1980) Antiemetics for patients treated with antitumor chemotherapy. Cancer Clin Trials 3: 363–367

    PubMed  CAS  Google Scholar 

  115. Winokur SH, Baker JJ, Lokey JL, Price NA, Bowen J (1981) Dexamethasone in the treatment of nausea and vomiting from cancer chemotherapy. J Med Assoc Ga 70: 263–264

    PubMed  CAS  Google Scholar 

  116. Zambetti M, Bajetta E, Bidoli P, Verusio C (1985) Antiemetic activity of metoclopramide versus alizapride during cancer chemotherapy. Tumori 71: 609–614

    PubMed  CAS  Google Scholar 

  117. Zylberait D, Krulik M, Audebert AA, Debray J (1981) Essai comparatif de deux medicaments dans le traitement des vomissements induits par la chimiotherapie anti-cancéreuse. Semin Hopitaux 57: 47

    CAS  Google Scholar 

Download references

Authors
  1. Jørn Herrstedt
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Matti S. Aapro
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. John F. Smyth
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Albano Del Favero
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Ochsner Cancer Institute, 1514 Jefferson Highway, 70121-2483, New Orleans, LA, USA

    Richard J. Gralla

  2. Oncologia Medica, Policlinico Monteluce, Via Brunamonti, 06122, Perugia, Italy

    Maurizio Tonato  & Fausto Roila  & 

Rights and permissions

Reprints and permissions

Copyright information

© 1998 Springer-Verlag Berlin Heidelberg

About this paper

Cite this paper

Herrstedt, J., Aapro, M.S., Smyth, J.F., Del Favero, A. (1998). Corticosteroids, Dopamine Antagonists, and Other Drugs. In: Gralla, R.J., Tonato, M., Roila, F. (eds) Perugia Consensus Conference on Antiemetic Therapy. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-72137-3_1

Download citation

  • DOI: https://doi.org/10.1007/978-3-642-72137-3_1

  • Publisher Name: Springer, Berlin, Heidelberg

  • Print ISBN: 978-3-642-72139-7

  • Online ISBN: 978-3-642-72137-3

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation